1. Introduction
Katherine Fierlbeck, Janice Graham, and Matthew Herder
2. Transparency, Pharmaceuticals, and the Problem of Policy Change
Katherine Fierlbeck
3. Data Transparency and Pharmaceutical Regulation in Europe: Road to Damascus, or Room without a View?
Courtney Davis, Shai Mulinari, and Tom Jefferson
4. FDA and Health Canada: Similar Origins, yet Divergent Paths and Approaches to Transparency
Margaret McCarthy and Joe Ross
5. Clinical Trial Data Transparency in Canada: Mapping the Progress from Laggard to Leader
Marc-Andre Gagnon, Matthew Herder, Janice Graham, Katherine Fierlbeck, and Anna Danyliuk
6. How Clinical Study Information Transparency Can Fail to Serve Its Purpose, and How the Essential Medicines Concept Can Help
Nav Persaud
7. Speak No Secrets: (Non)transparency in Health Canada's Communications about Pharmaceutical Regulation
Joel Lexchin
8. Economic Ghost-Management in the Pharmaceutical Sector
Marc-Andre Gagnon
9. Balancing the Privacy Rights of Research Participants with the Public Interest in Clinical Drug Trials Data in the Context of Rare Diseases
Kanksha Mahadevia Ghimire and Trudo Lemmens
10. The European Registration of the Pandemic Influenza Vaccine Pandemrix: A Case Study of the Consequences of Poor Clinical Data Transparency
Tom Jefferson
11. Sharing Data and Ideas for Good Health: How Researchers Can Sustain an Ethical and Transparent Health System
Rita Banzi
12. Conclusion
Katherine Fierlbeck, Janice Graham, and Matthew Herder
